Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): A phase 3 biological assignment trial

The Lancet Oncology

Volumn 12, Issue 13, 2011, Pages 1195-1203

  Krishnan, Amrita ^a   Pasquini, Marcelo C ^b   Logan, Brent ^b   Stadtmauer, Edward A ^c   Vesole, David H ^d   Alyea, Edwin ^e   Antin, Joseph H ^e   Comenzo, Raymond ^f   Goodman, Stacey ^g   Hari, Parameswaran ^b   Laport, Ginna ^h   Qazilbash, Muzaffar H ⁱ   Rowley, Scott ^d   Sahebi, Firoozeh ^a   Somlo, George ^a   Vogl, Dan T ^c   Weisdorf, Daniel ^j   Ewell, Marian ^k   Wu, Juan ^k   Geller, Nancy L ^l   Horowitz, Mary M ^b   Giralt, Sergio ^m   Maloney, David G ⁿ   more..

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j UNIVERSITY OF MINNESOTA   (United States)

^k EMMES CORPORATION   (United States)

^l NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LIVER ENZYME; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ATAXIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; CAPILLARY LEAK SYNDROME; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG TOLERABILITY; DYSPNEA; FEMALE; GRAFT FAILURE; HEART ARRHYTHMIA; HEART DISEASE; HEART LEFT VENTRICULAR DYSFUNCTION; HEMORRHAGIC CYSTITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; HYPOXIA; INTERMETHOD COMPARISON; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEUROPATHY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEIZURE; SENSORY NEUROPATHY; SOMNOLENCE; SURVIVAL RATE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 82555179157     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70243-1     Document Type: Article

References (29)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996, 335:91-97. for the Intergroupe Français du Myélome.
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
3. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003, 349:2495-2502.
4. Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010, 115:1113-1120.
5. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108:3289-3294.
6. Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006, 135:158-164.
7. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007, 25:2434-2441.
8. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006, 354:1021-1030.
9. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996, 88:2787-2793.
10. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995, 13:1312-1322.
11. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991, 325:1267-1273. for the European Group for Bone Marrow Transplantation.
12. Reynolds C, Ratanatharathorn V, Adams P, et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 2001, 27:801-807.
13. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003, 102:3447-3454.
14. Weisdorf D, Carter S, Confer D, Ferrara J, Horowitz M Blood and marrow transplant clinical trials network (BMT CTN): addressing unanswered questions. Biol Blood Marrow Transplant 2007, 13:257-262.
15. Logan B, Leifer E, Bredeson C, et al. Use of biological assignment in hematopoietic stem cell transplantation clinical trials. Clin Trials 2008, 5:607-616.
16. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
17. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
18. Lahuerta JJ, Martinez-Lopez J, Serna JD, et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000, 109:438-446.
19. Cox D Regression models and life tables. J R Stat Soc Series B Stat Methodol 1972, 4:187-200.
20. Barlogie B, Shaughnessy JD, Crowley J Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008, 359:210-212.
21. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006, 354:1021-1030.
22. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007, 356:1110-1120.
23. Rosiñol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112:3591-3593.
24. Bjorkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011, 29:3016-3022.
25. Bruno B, Storer B, Patriarca F, et al. Long-term follow up of a comparison of non-myeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011, 117:6721-6727.
26. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
27. Kroger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004, 104:3361-3363.
28. Lioznov M, El-Cheikh J, Hoffmann F, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010, 45:349-353.
29. Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 2009, 23:605-607.